Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs.  Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.
HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
FOLEY HOAG LLP
1717 K Street, N.W., Suite 1200, Washington, DC, 20006, US
PAUL KIM